Marksans Pharma Ltd
NSE:MARKSANS
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
132.95
318.35
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one MARKSANS stock under the Base Case scenario is 170.92 INR. Compared to the current market price of 308.65 INR, Marksans Pharma Ltd is Overvalued by 45%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Marksans Pharma Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for MARKSANS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Marksans Pharma Ltd
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Marksans Pharma Ltd
Balance Sheet Decomposition
Marksans Pharma Ltd
Current Assets | 18.6B |
Cash & Short-Term Investments | 7.1B |
Receivables | 4.6B |
Other Current Assets | 7B |
Non-Current Assets | 8.2B |
PP&E | 6.8B |
Intangibles | 1B |
Other Non-Current Assets | 331.1m |
Current Liabilities | 3.9B |
Accounts Payable | 2.7B |
Short-Term Debt | 290.9m |
Other Current Liabilities | 924.8m |
Non-Current Liabilities | 2.3B |
Long-Term Debt | 1.9B |
Other Non-Current Liabilities | 360.3m |
Earnings Waterfall
Marksans Pharma Ltd
Revenue
|
22.7B
INR
|
Cost of Revenue
|
-10.6B
INR
|
Gross Profit
|
12.1B
INR
|
Operating Expenses
|
-8.1B
INR
|
Operating Income
|
4B
INR
|
Other Expenses
|
-702m
INR
|
Net Income
|
3.3B
INR
|
Free Cash Flow Analysis
Marksans Pharma Ltd
INR | |
Free Cash Flow | INR |
MARKSANS Profitability Score
Profitability Due Diligence
Marksans Pharma Ltd's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
Score
Marksans Pharma Ltd's profitability score is 61/100. The higher the profitability score, the more profitable the company is.
MARKSANS Solvency Score
Solvency Due Diligence
Marksans Pharma Ltd's solvency score is 97/100. The higher the solvency score, the more solvent the company is.
Score
Marksans Pharma Ltd's solvency score is 97/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MARKSANS Price Targets Summary
Marksans Pharma Ltd
According to Wall Street analysts, the average 1-year price target for MARKSANS is 290.19 INR with a low forecast of 267.65 INR and a high forecast of 319.2 INR.
Dividends
Current shareholder yield for MARKSANS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
MARKSANS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Marksans Pharma Ltd. engages in the research, manufacture, marketing, and sale of pharmaceutical formulations. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2002-04-03. The firm operates through the manufacture of pharmaceutical formulation segment. The firm is primarily engaged in the research, manufacturing and marketing of generic pharmaceutical formulations with three state-of-the-art facilities in India, the United Kingdom and the United States. The company marks its presence across different therapeutic areas in the region, such as pain management, diabetes, cough and cold, neurology, cardiovascular and hormonal treatment. The firm has a manufacturing facility for the manufacture of oral solid tablets, soft gelatin capsules and hard capsules in Goa. The company also manufactures non-sterile liquids, ointments and powder products and caters to the United Kingdom, West Africa and the Middle East, which is located in the United Kingdom. The firm has spread its facility to over 7000 square meters and manufactures tablets and capsules in the United States.
Contact
IPO
Employees
Officers
The intrinsic value of one MARKSANS stock under the Base Case scenario is 170.92 INR.
Compared to the current market price of 308.65 INR, Marksans Pharma Ltd is Overvalued by 45%.